Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.
By D. Speiser, D. Liénard, N. Rufer, V. Rubio‐Godoy, D. Rimoldi, F. Lejeune, A. Krieg, J. Cerottini, P. Romero. Journal of Clinical Investigation, 2005
663 citations recorded by the source corpus.
Subfields: Immunology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/b894795eba87a380a7e3a091b25e0c8490f1eb71
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Molecular Biology
Citations in the corpus
- Cancer immunotherapy (2012, background): “It is neither yet clear thatmassive lymphodepletion is actually required for optimal efficacy of adoptively transferred T cells, nor that high-dose IL-2 is absolutely required.”
- Therapeutic cancer vaccines. (2010, background): “Only ex vivo loading of preactivated DCs with short peptides (136) or replacement of the CD4+ helper signal with agonist antiCD40 Ab, with or without TLR ligand poly I:C (137, 138) or with CpG (139), can circumvent such tolerance induction against short, MHC class I–binding peptides in mice or patie”
- Therapeutic potential of Toll-like receptor 9 activation (2006, methodology): “5 mg stimulated strong and rapid CD8 T-cell responses to a Melan-A tumour peptide antigen when used with Montanide (Seppic) as a cancer vaccine adjuvan”
- Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines (2008, background): “aspx?CdrID=38660">CpG 7909 — a TLR9 ligand — enhanced not only the magnitude but also the activation status of the Tc response to a minimal Tc peptide vaccine in IF”
- Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. (2011, methodology): “Furthermore, we took advantage of the strong immunogenicity of vaccination with peptide plus CpG (19).”